Redefining Cardiovascular Replacement

Xeltis is a clinical-stage medical device company pioneering a restorative approach in cardiovascular therapy.

RestoreX™, Xeltis technology platform, is the world’s first polymer-based technology designed to enable natural restoration of cardiovascular function, through a therapeutic approach called Endogenous Tissue Restoration (ETR).

Potentially addressing

millions of patients / year

Xeltis is currently investigating applications of its innovative approach to restore heart valves and small diameter blood vessels.

Over 25 patients implanted

  • Restorative small diameter vascular applications, including Coronary Artery Bypass Grafts (CABG) are showing promising results in preclinical trials.

  • The first few patients receiving Xeltis pediatric vascular grafts have now reached their 5-year follow-up.

  • Xeltis restorative heart valves have been in trials for years, including two clinical trials in EU, Asia and in the USA.

Xeltis’ Progression

2006

  • Swiss Xeltis founded as Univeristy of Zurich spin-off

2012

  • Xeltis merges with Dutch Qtis/e, becoming today’s Xeltis

2013

  • Feasibility clinical trials start (patch and graft)

2014

  • Series B financing round closed

2016

  • Pulmonary valve enters clinical trial phase
  • Aortic valve enters preclinical trial phase

2017

  • US FDA approved Investigational Device Exemption (IDE) for PV Early Feasibility Study (EFS)
  • Series C financing round closed

2018

  • Small diameter blood vessels enter preclinical trial phase
  • Patient enrolment completed for EFS

Xeltis has been recognized as a breakthrough medtech start-up